	Application No.	Applicant(s)	
No. Co. Co. Co. Co.	09/760,380	BELLEAU ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Thomas McKenzie, Ph.D.	1624	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) of NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIC of the Office or upon petition by the applicant. See 37 CFR 1.313	OR REMAINS) CLOSED in this apport of the appropriate communication GHTS. This application is subject to	olication. If not included will be mailed in due course. THIS	live
1. 🖂 This communication is responsive to amendments of 4/19/	<u>′04</u> .		
2. X The allowed claim(s) is/are <u>35-50, 55-72,74 and 75</u> .			
3. The drawings filed on are accepted by the Examiner.			
 4. Acknowledgment is made of a claim for foreign priority und a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have and the priority documents have are certified copies of the priority documents have are certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONMETHIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which gives are comply including changes required by the Notice of Draftsperson and including changes required by the Notice of Draftsperson and including changes required by the attached Examiner's Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.8 each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such in the each sheet. Replacement sheet(s) should be labeled as such at the each sheet. Replacement sheet(s) should be labeled as such at the each sheet. Replacement sheet(s) should be labeled as such at the each sheet.	been received. been received in Application No. <u>08</u> uments have been received in this r f this communication to file a reply of this application. ted. Note the attached EXAMINER's reason(s) why the oath or declarate be submitted. be submitted. on's Patent Drawing Review (PTO-9 Amendment / Comment or in the Off the process of the	complying with the requirements S AMENDMENT or NOTICE OF ion is deficient. 148) attached ffice action of gs in the front (not the back) of). sust be submitted. Note the	
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 7/4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary (Paper No./Mail Date), 7. ☑ Examiner's Amendm		

EXAMINER'S AMENDMENT

Page 2

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee. Authorization for this examiner's amendment was given in a telephone interview with Brion Heaney on 6/21/04. The application has been amended as follows: Please replace the first sentence of the specification with,

"This application is a continuation of application serial no. 08/466,329, filed June 6, 1995, which is now US Patent No. 6,175,008, which is a continuation-in-part of application serial no 08/040,163, filed March 29, 1993, which is now US Patent 5,466,806, which is a continuation-in-part of application serial no. 07/564,160 filed August 7, 1990, now abandoned, which is a continuation-in-part of applications nos. 07/308,101 filed February 8, 1989, which is now US Patent No. 5,047,407, and 07/546,676 filed June 29, 1990, which is now US Patent No. 5,041,449, which is a continuation of application serial no 07/179,615, filed April 11, 1988, now abandoned."

Statement of Reasons for Allowance

2. Claims 35-50, 55-72, 74, and 75 are allowed. The following is an Examiner's statement of reasons for allowance: Applicants' comments concerning

Art Unit: 1624

the interview of 2/12/03 are correct. All the monocyclic compounds were searched and are contained within the elected subject matter. This includes the 1,3,5-triazines, the 1,2,4-triazines, the pyridin-2-ones, the 1,2,4-triazoles, the imidazoles, and the pyrroles. Thus, the objection concerning non-elected subject matter, made in point #3 of the previous office action, was improper and is withdrawn. The Examiner regrets the oversight and the subsequent error. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance".

3. Information regarding the status of an application should be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free). All Post-Allowance correspondence concerning this application must be mailed to the following address:

Application/Control Number: 09/760,380

Art Unit: 1624

Page 4

Box Issue Fee

Commissioner for Patents

Washington, DC 20231.

Such correspondence (amendments under 37 CFR 1.312, IDS statements, formal drawings etc) also may be faxed to the Office of Patent Publications at (703) 308-5083. Sending Post-Allowance papers to Technology Center 1600 will only cause

delays in matching papers with the case.

Thomas McKenzie, Ph.

Patent Examiner
Art Unit 1624

TCMcK/me